RecruitingPhase 3NCT07750158
Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease
Sponsor: Exelixis
Bridgewater, NJ · East Brunswick, NJ · Edison, NJ · +10 more sites